FDA Spent $65.9M on Biosimilars Activities

Wednesday, September 30, 2015


An interim report shows that the FDA has conducted nearly 90 meetings with more than 50 drug companies interested in producing biosimilar products since 2013 at a cost of $65.9 million.

The report, ordered by Congress, showed the agency met with and reviewed potential IND applications with 33 drugmakers in 2013, 48 in 2014 and added four more in 2015.

View All News »